Key result
Novel antiplatelet therapies targeting primary platelet adhesion-signaling receptors like GPIb-IX-V and GPVI may improve antithrombosis with minimal bleeding compared to current clinical drugs.
Design
Review
Authors
Loading...
Supports pursuit of GPIb/GPVI-targeted agents; leaves open whether benefits translate to patients.
This review highlights the potential of targeting primary platelet adhesion-signaling receptors (GPIb-IX-V and GPVI) to develop novel antiplatelet therapies that minimize bleeding risks.
Metharom et al. (2015) conducted a review in Athero/thrombotic disease. Antiplatelet therapy was evaluated. Novel antiplatelet therapies targeting primary platelet adhesion-signaling receptors like GPIb-IX-V and GPVI may improve antithrombosis with minimal bleeding compared to current clinical drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: